Rick Bedlack MD PhD, Director of the Duke ALS Clinic in North Carolina, talks ALS clinical trials: where we are and where we need to go to develop better treatment strategies for the disease.

Klaus Nave PhD, Director of the Max Planck Institute of Experimental Medicine, discusses the emerging role of oligodendrocytes in ALS and potential treatment strategies going forward. Read more: http://blogs.als.net/post/2012/10/29/ALS-dressed-to-the-C9s.aspx

Rachael Marsden RN MSc, Clinical Care Coordinator at the Oxford MND Centre in England, did not know when she answered a help wanted ad that she would transform care and management of people with ALS in Turkey.

Athanase Millogo, MD of Bobo-Dioulasso University Teaching Hospital in Burkina Faso, hopes to make a difference for people with ALS beyond his nation's borders. Read more: http://blogs.als.net/post/2012/06/21/TROPALS-Circle-In-the-Sand.aspx

Guðjón Sigurðsson, pALS and ALS/MND International Alliance Chairman, talks about how he hopes to make life better for people with ALS in Iceland and elsewhere around the globe.

Akshay Anand PhD of the Postgraduate Institute of Medical Education and Research in Chandigarh, India, hopes to discover the secret behind the longevity of certain people with ALS/MND. Read more: http://blogs.als.net/post/2012/06/21/ALS-a-brief-history-of-more-time.aspx

Miriam Bucheli PhD of the Universidad San Francisco de Quito in Ecuador is on the hunt for environmental factors that might contribute to ALS including lead exposure. Read more: http://blogs.als.net/post/2012/07/05/Climb-every-mountain.aspx

Stanley Appel MD Director of the Methodist Neurological Institute in Texas, talks about the emerging role of cytotoxic microglia in ALS and potential treatment strategies to combat them. Read more: http://blogs.als.net/post/2011/12/16/Symphony-in-M.aspx